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INTRODUCTION:
The goals of this proposal are to 1) determine if targeting the nuclear EGFR (nEGFR) signaling pathway can increase the efficacy of anti-EGFR antibody based therapies in non-small cell lung cancer (NSCLC) and 2) determine if nEGFR can serve as a prognostic factor in NSCLC.
The EGFR is a ubiquitously expressed receptor tyrosine kinase (RTK) involved in the etiology of NSCLC. With this, intense efforts have been undertaken to stop EGFR function. These efforts have been highly fruitful as four drugs, including two small tyrosine kinase inhibitors (TKIs, gefitinib and erlotinib) and two antibodies (cetuximab and panitumumab), have moved to the clinic to target EGFR in NSCLC patients. In 2004, the identification of specific genetic mutations within the EGFR kinase domain of adenocarcinomas of the lung that predict response to EGFR-TKIs represented a landmark development in the EGFR field. Unfortunately, no such mutations that predict response to cetuximab have yet been identified. Clinical trials (FLEX trial 1 ) investigating cetuximab in NSCLC showed clinical benefit. However, not all patients respond to cetuximab therapy and most acquire resistance to cetuximab.
It is well established that the EGFR can rely on two distinct compartments of signaling: 1) Classical membrane bound signaling (classical EGFR pathway) 2 and 2) nuclear signaling (nEGFR pathway) 3 . In the nEGFR pathway, recent data suggests that the EGFR is phosphorylated by Src family kinases (SFKs) 4 ,5 and AKT 6 , which are necessary, early, events for trafficking EGFR from the membrane to the nucleus. In the nucleus EGFR is able to promote the transcription of genes essential for cell proliferation and cell cycle regulation [6] [7] [8] [9] [10] [11] [12] . To explore molecular mechanisms of resistance to cetuximab in NSCLC our lab developed a series of cetuximab-resistant models using NSCLC cancer lines 13 . During investigations into potential molecular mechanisms of resistance we found that NSCLC tumor cells that acquired resistance to cetuximab had increased SFK activity 14 and increased nEGFR 5 . Further investigation revealed that SFKs regulate EGFR translocation to the nucleus 5 and the nuclear activity of EGFR contributes to resistance to cetuximab therapy 5 . However, this preliminary work has led to several questions that form the focus of this application: 1) Can blocking SFK and AKT activity decrease nuclear translocation of the EGFR in vivo, 2) will this lead to increased expression of EGFR on the cell membrane, 3) will this increase sensitivity to cetuximab therapy and 4) what is the prevalence of nEGFR in NSCLC patient biopsies and can it serve as a prognostic factor? In this proposal we hypothesize that nEGFR contributes to NSCLC resistance to cetuximab and that targeting nEGFR, by abrogating its translocation to the nucleus via SFK or AKT inhibition, followed by targeting membrane bound EGFR with cetuximab will increase therapeutic response of NSCLC tumors to cetuximab. To test this hypothesis we propose the following specific aims:
to cetuximab therapy providing further rationale for the investigation of nEGFR kinase independent functions in cetuximab resistance.
De Novo derived, cetuximab resistant tumors have increased nuclear EGFR:
One criticism we often receive is that our model of cetuximab resistance was developed in vitro and it is not clear whether nuclear EGFR would be present in resistant tumors developed in vivo. To mimic the development of acquired resistance to cetuximab in the clinical setting we have previously developed numerous de novo acquired resistant models in vivo by treating established cetuximab sensitive tumors with continued cetuximab therapy until resistant tumor emerge 17 . As depicted in Figure  2 , tumors treated with IgG grew rapidly, while tumors treated with cetuximab displayed initial growth control. Acquired resistance was observed at approximately 30-60 days in 65% of tumors, where there was marked tumor growth in the presence of continued cetuximab therapy. IHC Analysis of these tumors indicated that 7/9 had increased nEGFR expression as compared to IgG treated tumors (Figure 2 ). This work has been replicated in other SCC models including de novo tumors established from the cetuximab sensitive cell lines H292 and SCC1.
Chemically induced lung tumors have increased nuclear EGFR:
To make more robust models of lung cancers harboring nuclear EGFR we created chemically derived tumors using NTCU as previously described. This tumor model will be used in Aim 2 for functional targeting studies of EGFR. Briefly, we started a collaboration with Dr. Ming You (MCW Cancer Center Director and consultant) who was the first to use NTCU to generate SCC in the mouse lung 18 . He determined that FVB/N mice gave approximately four SCC lesions/mouse eight months after treatment with NTCU. Further, the histopathology of the mouse lung SCC is similar to that seen in humans with well-defined pathological development from bronchial hyperplasia to SCC. To determine if chemically derived LSCC tumors in mice harbor nEGFR we stained 20 independent tumors and analyzed for nEGFR expression ( Figure  3B) . Strikingly, the results showed that like human ( Figure 3A) , mouse LSCC harbored nEGFR whereas normal tissue had no nEGFR expression. Finally, of note, cetuximab does not react with the mouse EGFR. To overcome this experimental problem we have obtained an MTA from ImClone that has generated a murine anti-EGFR antibody, termed ME1. This antibody binds the murine EGFR and inhibits its activity 19 .
Specific Aim 2:
Determine if targeting nEGFR, via SFK or AKT inhibition, can increase therapeutic response of nEGFR positive, cetuximab-resistant NSCLC tumors to cetuximab. In specific Aim 1 we originally aimed to use cells that developed acquired resistance to cetuximab therapy in vitro. However we have determined that de novo and chemically derived tumors have increased nuclear EGFR and that these models may increase the robustness of targeting nuclear EGFR in Aim 2. This will serve as the final focus of our work in year 3 of this grant.
Specific Aim 3:
Determine the prevalence of nEGFR protein expression in NSCLC using IHC and AQUA analyses and determine if it serves as a prognostic factor in NSCLC. The focus of this aim was to use two NSCLC TMAs with various stages of NSCLC. In a first effort we focused our time on the 88 patient TMA that contained only stage I and II patients. The findings from this study have been reported last year and published. We have expanded on this and turned our attention to determining if nuclear EGFR could serve as a predictive factor for cetuximab response in LSCC.
This was written as an aim in our recent R01 application and is placed here for completeness of design.
Determine if nEGFR expression is a predictive biomarker for cetuximab resistance in advanced LSCC.
To accomplish this aim we will determine nEGFR levels in human LSCC tumor specimens and test for a correlation with cetuximab clinical benefit. We will examine nEGFR expression in human tumor specimens (tissue microarray) obtained from the University of Chicago iBridge Network.
Hypothesis -We hypothesize that the clinical benefit of cetuximab in advanced LSCC patients will be predicted by nEGFR expression.
Rationale -Randomized trials have documented that the addition of cetuximab to conventional chemotherapy in advanced NSCLC results in minimal improvements in clinical outcome 20 . We and others have hypothesized that the marginal benefit observed is a consequence of inadequate patient selection; a robust predictive biomarker for cetuximab efficacy in NSCLC has not been identified 21, 22 . Total EGFR expression has been correlated with cetuximab survival benefit, however, the predictive power is quite modest 23 . We have recently shown that nEGFR is a prognostic factor in early stage NSCLC 24 . Further, in experimental model systems, we have shown that elevated nEGFR leads to cetuximab resistance in a variety of cancers 5, 14, [25] [26] [27] . Therefore, it is biologically plausible that nEGFR may be a predictive biomarker of cetuximab efficacy and permit optimal patient selection for cetuximab use in advanced NSCLC.
Clinical Sample Set -We will confirm the prognostic significance of nEGFR in advanced LSCC (stage IV) and determine if nEGFR is a predictive biomarker for cetuximab efficacy. In order to do so, we will employ the thoracic oncology research program standard operating procedure (SOP) within the iBridge network (http://www.ibridgenetwork.org) directed by Dr. Salgia (collaborator) at the University of Chicago. The iBridge network SOP is a large research bioinformatics platform representing more than 4000 total lung cancer samples and tissue microarrays. Specimens are linked to comprehensive clinical information including outcomes (RR, OS, PFS) as well as characteristics such as age, sex, race, stage at initial diagnosis, and therapeutic history. The dataset has contributed to several large-scale lung cancer analyses similar to the analysis proposed herein 28, 29 . Among regional utilizers/contributors to the iBridge network, cetuximab was frequently employed in the advanced NSCLC population prior to the availability of phase III trial evidence of minimal clinical benefit. Consequently, we have identified 200 advanced LSCC patients treated with carboplatin/paclitaxel/cetuximab. An additional 300 advanced LSCC patients treated with carboplatin/paclitaxel have been identified. To extrapolate from the Lynch trial, there was no difference in overall survival between chemotherapy with or without cetuximab 30 . However, our hypothesis is that the predictive value of cetuximab response would be dependent on nuclear or non-nuclear localization of EGFR. As can be appreciated, the iBridge network has the SOP of our database as well as the tumor tissue repository. This was initially created by Dr. Salgia and his colleagues with ARRA funding and has been made available to anyone for free. Since establishment, the initial SOP has been licensed by over 80 institutions (including Harvard, Hopkins, Yale, Boston University, Columbia, etc). The SOP is available in Microsoft Access, Oracle based system, as well as RedCap. In the metropolitan Chicago area, we have a combined effort with Rush, UIC, North Shore, Ingalls Hospital, and our phase II consortium (containing 13 affiliates).
Correlation of EGFR localization and clinical outcome -Tissue microarrays will be prepared from this patient cohort through the University of Chicago Pathology Core. We will then stain, using several EGFR antibodies that have been used in analysis of nEGFR 24 . In particular, we will determine the expression of cytoplasmic/membranous versus nEGFR and correlate with clinical benefit rate. Expected results -We expect that nEGFR expression will be prognostic in advanced LSCC patients with lower clinical benefit rates with both chemotherapy and the combination of chemotherapy and cetuximab in nEGFR expressors compared to nEGFR non-expressors. Critically, we expect that nEGFR expression will be associated with no improvement in clinical benefit rate with the addition of cetuximab. In contrast, we anticipate that advanced LSCC patients without nEGFR expression will significantly benefit from the addition of cetuximab.
Statistical analysis -Power analysis is based on clinical benefit rate, defined by the rate of response plus stable disease at 12 weeks. The four groups for comparison are (1) nEGFR negative treated with chemotherapy (CT), (2) nEGFR negative treated with cetuximab and chemotherapy (CTX+CT), (3) nEGFR positive treated with CT and (4) nEGFR positive treated with CTX + CT. Based on our preliminary work, we expect 40% or more samples to be nEGFR negative in this advanced stage population. The clinical benefit rates of both CT and CTX+CT are expected to be about 30% for nEGFR positive groups (i.e. there will be no benefit to the addition of CTX). The clinical benefit rate from CT is estimated to be higher in the nEGFR negative group by about 5%-10% (prognostic). We hypothesize the clinical benefit rate will be higher with the addition of CTX in the nEGFR negative cohort (predictive). For statistical analysis, we estimate the absolute magnitude of the CTX benefit in the nEGFR negative cohort to be approximately 20%. We perform our power analysis based on detecting this predictive effect of nEGFR status using an interaction logistic regression model, which is to detect statistically significant interaction between nEGFR status and cetuximab. The type I error is set at 10% level and the resulting powers range from 0.78 or 0.92 depending on the possible values for the proportion of nEGFR negative, clinical benefit rates of CT in nEGFR negative and positive groups (see Tables XX and XX in the appendix). The calculation is based on 200 samples of CT+CTX and 300 samples of CT alone. We will conduct our analysis based on logistic regression models.
Potential Pitfalls and Alternative Approaches -Our laboratory reported that nEGFR leads to resistance to cetuximab therapy. However, which nuclear function of EGFR that plays a role in this process is not yet known. To investigate this, we developed a nEGFR mutant that lacks the ability to mediate transcription. This results in a potential pitfall in Aim 2A, since tumors lacking nEGFR transcriptional functions may grow differently from tumors overexpressing EGFRWT. In order to determine cetuximab response we will do both time-matched and size-matched cetuximab response experiments and measure the tumor growth delay as compared to the EGFRWT control. Due to the heterogeneity of the studied patient population, clinical outcomes (RR, OS, PFS) will vary. This potential pitfall is limited by design with inclusion of only metastatic patients. If statistical significance is compromised by patient heterogeneity in Aim 2B, a number of approaches may be taken to increase power and elucidate the predictive value of nEGFR expression including time-to-event analysis. Additional tissue samples are available from the University of Wisconsin if analyses are underpowered (see Traynor letter) . Moreover, analysis of nEGFR expression as a continuous variable and/or examination of the cytoplasmic-to-nEGFR ratio may provide opportunities to enhance statistical power of correlations between EGFR expression and localization with clinical outcomes.
KEY RESEARCH ACCOMPLISHMENTS:
• Axl receptor tyrosine kinase is implicated in EGFR nuclear trafficking • EGFR can mediate cetuximab resistance independent of its kinase activity • Chemically derived tumors harbor nuclear EGFR • De novo derived cetuximab resistant tumors harbor nuclear EGFR • AKT inhibition is not robust in preventing nuclear EGFR trafficking
CONCLUSIONS:
NSCLC is a deadly disease that is driven by a multitude of factors. One of these factors is the epidermal growth factor receptor (EGFR). One of the most prominent molecular targeting agents to the EGFR is the antibody cetuximab. However, most patients develop resistance to this antibody. We have found in models of cetuximab resistance that the EGFR changes its location, to the nucleus, where it is not accessible to the large antibody. Our work over the last several years has discovered how to target the nEGFR, by blocking its translocation to the nucleus through Src Family Kinase blockade.
In the First year we have determined that nEGFR can serve as a prognostic factor in early stage NSCLC patients. We are building on this finding to see if nEGFR can serve as a prognostic factor for late stage patients, a goal of Aim 3. Secondly we have determined that we can target nEGFR in vivo and redistribute to the membrane in vivo, a critical first step for re-sensitizing to cetuximab. Finally, we have developed a new avenue by developing a novel EGFR mutant that lacks its transcriptional potential. This will allow us to directly test the role of nEGFR in biology and cetuximab resistance.
In the Second year we have determined several key findings. The first is that Axl receptor tyrosine kinase is a critical mediator of nuclear translocation of the EGFR. This novel finding may indicate that target Axl may serve as a secondary approach to block the nuclear functions of EGFR. Secondly we found that tumors that develop resistance in vivo have nuclear EGFR and further, chemically derived tumors harbor nuclear EGFR. Thirdly, we have found that targeting nuclear EGFR by blocking the AKT pathway had minimal effects as compared to blocking the Src Family Kinases. Further investigations will focus on SFK blockade as well as targeting Axl.
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Introduction
Approximately 15% to 20% of all breast cancers lack expression of the estrogen receptor, progesterone receptor, and HER2, and are thus considered to be triplenegative breast cancers (TNBC; refs. 1, 2). Although a high percentage of patients with TNBC initially respond to conventional chemotherapy, they tend to have a higher rate of relapse and worse prognosis as compared with other breast cancer subtypes (1, 2) . In efforts to identify new molecular targets in TNBC, various groups have performed gene expression profiling studies and identified that the EGF receptor (EGFR) is commonly overexpressed (3) (4) (5) (6) . Although inhibition of EGFR activity has yielded modest clinical success in TNBC, substantial gains in clinical response rates have not been achieved (7, 8) . Thus, improving the efficacy of anti-EGFR therapy in TNBC is imperative.
Classically, EGFR functions as a plasma membranebound receptor tyrosine kinase that initiates growth and survival signals (9) . However, studies over the last 15 years have identified that EGFR can be localized and function from intracellular organelles, one of which includes the nucleus (10, 11) . Within the nucleus, EGFR can function as a cotranscription factor to regulate genes involved in tumor progression (10, 11) , in addition to functioning as a nuclear kinase to enhance DNA replication and repair (12) (13) (14) . These nuclear functions have been linked to three parameters of tumor biology: (i) inverse correlation with overall survival in numerous cancers (15) (16) (17) (18) (19) (20) , (ii) resistance to therapeutic agents including radiation (12, (21) (22) (23) (24) , chemotherapy (12, 13, 24) , and anti-EGFR therapies gefitinib (25) and cetuximab (26) , and (iii) enhanced tumor growth (27, 28) . These findings suggest that tumors rely on two distinct compartments of EGFR signaling to sustain their oncogenic phenotype: (i) classical membrane-bound EGFR signaling, and (ii) nuclear EGFR (nEGFR) signaling.
Previous work from our laboratory has identified that non-small cell lung cancer (NSCLC) cells that have acquired resistance to cetuximab express increased nEGFR and Src Family Kinase (SFK) activity (26, 29) . SFK inhibition blocked nEGFR translocation in cetuximab-resistant cells, and led to an increase in plasma membrane EGFR expression and enhanced sensitivity to cetuximab (26, 30) . Furthermore, the SFK-dependent phosphorylation site on EGFR, tyrosine 1101 (Y1101), was identified to play a critical role in initiating EGFR's nuclear transport (30) . These studies suggest that nEGFR is a critical molecular determinant for cetuximab resistance and that SFKs play an important role in regulating nEGFR translocation.
On the basis of these previous studies, we hypothesized that nEGFR may promote intrinsic resistance to cetuximab in TNBC. To examine this question, a battery of TNBC cell lines and human tumors were screened and found to express nEGFR. Although TNBC cell lines were notably resistant to cetuximab therapy, all lines retained dependency on EGFR for proliferation. Furthermore, SFKs influenced nEGFR transport in TNBC, where the overexpression of a negative regulator of Src decreased EGFR activity at tyrosine 1101 and inhibited nEGFR translocation. Interestingly, the creation of stable cell lines overexpressing each SFK demonstrated that all SFKs could promote nEGFR translocation. Treatment of TNBC cell lines and xenograft tumors with the anti-SFK therapeutic dasatinib inhibited nEGFR translocation, and enhanced surface level EGFR accumulation. Importantly, pretreatment of TNBC cell lines with dasatinib greatly enhanced the sensitivity of cetuximab-resistant TNBC cell lines to cetuximab. Collectively, our data suggest that abrogating nEGFR translocation with SFK inhibitors may greatly enhance the efficacy of cetuximab in TNBC.
Materials and Methods
Cell lines
The human breast cancer cell lines SKBr3, BT474, BT549, MDAMB231 and MDAMB468, MCF-7, and the Chinese hamster ovary cell line CHOK1 were purchased from American Type Culture Collection in November 2010. SUM149, SUM229, and SUM159 were purchased from Asterand in November 2010. All cell lines were authenticated by the indicated source and not by our laboratory. All cell lines were maintained in their respective media (Mediatech Inc.) with 1% penicillin and streptomycin; SKBr3, BT549, and MDAMB231, Dulbecco's Modified Eagle's Medium with 10% FBS; BT474, RPMI-1640 with 10% FBS; SUM149, SUM229, and SUM159, F12K medium with 5% FBS, 1 mg/mL hydrocortisone and 5 mg/mL insulin; MDAMB468 and MCF-7, DMEM/F12K medium with 10% FBS; CHOK1 F12K medium with 10% FBS.
Antibodies, compounds, and TMAs
All antibodies were obtained from the following sources: EGFR (SC-03), pEGFR-1173 (SC-10168), HER2 (SC-284), SLAP (SC-1215), Histone H3 (SC-8654), horseradish peroxidase-conjugated goat-anti-rabbit immunoglobulin G (IgG), goat-anti-mouse IgG, donkey-anti-goat IgG, EGFR blocking peptide (SC-03 P) purchased from Santa Cruz Biotechnology Inc. SFK (CS2123), pSFK-Y419 (CS2101), pEGFR-Y1045 (CS2237), pEGFR-Y1068 (CS3777), pHER2-Y1221/1222 (CS2243), c-Cbl (CS2747), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; CS2118), calnexin (CS2679), and anti-Flag (CS8146) purchased from Cell Signaling Technology. pEGFR-Y1101 (ab76195) and EGFR (ab52894) purchased from Abcam. a-Tubulin purchased from Calbiochem. Dasatinib (BMS-354825, Sprycel) was purchased from LC Laboratories and cetuximab (C225, Erbitux) was purchased from University of Wisconsin Pharmacy (Madison, WI). EGF was purchased from Millipore. Two human TNBC tissue microarrays (TMA; #695711112B and #69572306) were purchased from TriStar Technology Group.
Cellular fractionation and immunoblotting analysis
Cellular fractionation and whole-cell lysis were performed and quantitated as previously described (26, 31) . ECL chemiluminescence detection system was used to visualize proteins. a-Tubulin, calnexin, and Histone H3 were used as loading and purity controls, respectively.
Immunoprecipitation
Cells were processed for immunoprecipitation as previously described (31) . Of note, 250 mg of protein and 2 mg of Src-like adaptor protein (SLAP) primary antibody were used for immunoprecipitation.
Plasmids constructs, transfection, and siRNA technology
The following vectors were kindly supplied: pcDNA3.0-caSrc, -wtSRC and -EGFR wild-type (WT) and -EGFRY1101F, Dr. J.Boerner (Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI); pcDNA3-SLAP, Dr. S. Roche (Centre de Recherche de Biochimie Macromol eculaire, Montpellier, France); pTRE2pur-HA-Fyn, -Hck, and -Lck, Dr. P.S. Mischel (University of California, San Diego, La Jolla, CA). WT human pDONR223-FGR (Plasmid 23877) and pDONR223-Blk (Plasmid 23940) were purchased from Addgene. pQCXIP-YES and -LYN as previously described (30) . All SFKs were subcloned into the PAC1/ AGEI restriction sites of the pQCXIP expression vector (Clontech). Both transient and stable transfections were performed using Lipofectamine LTX and Opti-MEM I (Life Technology). Stable transfection was commenced 48 hours posttransfection via addition of 500 ng/mL puromycin to the growth media. Single cell clones were chosen for expansion and validation for specific SFK expression.
For siRNAs, cells were transfected with 30 nmol/L siEGFR (ON-TARGETplus, SMART pool #L-003114-00, Dharmacon) or siNon-targeting (NT; ON-TARGETplus Non-targeting Pool, D-001810, Dharmacon) using Lipofectamine RNAiMAX (Life Technology) according to the manufacturer's instructions. Vehicle (Veh)-treated cells were treated with RNAiMAX only.
Cell proliferation assay
Crystal violet assay and Cell Counting Kit-8 (Dojindo Molecular Technologies) were performed as previously described (26, 32) . Cellular proliferation was measured 72 to 96 hours post siRNA and 96 hours post drug treatment.
Transmission electron microscopy
Cells were plated on glass cover slips at approximately 90% confluency. The pre-embedding labeling method was used for processing as previously described (33) . Specifically, 0.8% Triton X-100 was used for permeabilization and 7 mg/mL of EGFR primary antibody was used (SC-03, Santa Cruz Biotechnology). Cells were silver enhanced for 1.5 hour. Cells were sectioned onto copper grids at approximately 90 nm slices.
Immunofluorescence
Cells were processed for immunofluorescence staining of EGFR as previously described (31) . Primary antibody: EGFR (SC-03), 1:100. Secondary antibody (Life technologies): Alex Fluor 546 at 1:600 for 30 minutes to 1 hour. All cells were mounted with ProLong Gold Antifade Reagent with 4 0 , 6-diamidino-2-phenylindole (DAPI; Life Technologies). Confocal immunofluorescence microscopy was performed using an A1 Nikon confocal microscope (Â600). Z-slices were taken at 150 nm slices.
Nuance imaging analysis
For image analysis, EGFR (ab52894, 1:50) and anti-E Cadherin antibody (NCH-38, Dako at 1:100 dilution) were used for immunofluorescence staining. Images were acquired on the Nuance Multispectral Imaging System (Caliper Life Sciences, Â200). A spectral library composed of the fluorescent spectrum of each fluorophore was constructed from vehicle treated cells stained with each fluorophore individually. Images were analyzed on the inForm Image Analysis Software (Caliper Life Sciences) as previously described (34) by pathologist D. Yang. Relative expression of EGFR in each compartment was expressed as a ratio of proportion of counts in the high intensity bins (bins 6-10) divided by the proportion of counts in the low intensity bins (bins 1-5).
Immunohistochemistry
Cells were processed for immunohistochemistry (IHC) as previously described (32) . EGFR antibody (SC-03) was used at a 1:100 dilution. The nEGFR staining pattern was scored by pathologist (D. Yang) analysis at 5% increments by visual estimation at Â20 magnification. Cases with at least one replicate core containing at least 5% of tumor cells demonstrating strong nEGFR IHC protein expression were scored as nEGFR positive.
Flow cytometry
Cells were processed as previously described (26) . Cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences). Propidium iodide was added to each sample at a final concentration of 5 mg/mL. Histogram analysis was performed using FlowJo software (Tree Star Inc.).
Mouse xenograft model and tumor collection
Athymic nude mice (4-6-week-old females) were obtained from Harlan Laboratories. All animal procedures and maintenance were conducted in accordance with the institutional guidelines of the University of Wisconsin. Twelve mice were injected in the dorsal flank with 2 Â 10 6 MDAMB468 cells. Once tumors reached 100 mm 3 , mice were randomized into treatment groups: vehicle (sodium citrate monobasic buffer) or dasatinib (50 mg/kg/d). Mice were treated once daily for 4 days via oral gavage. Tumor volume measurements were evaluated by digital calipers and calculated by the formula (p)/6 Â (large diameter) Â (small diameter) 2 . Tumors were collected, processed, and stained as previously described (32, 35) .
Statistical analysis
Student t tests were used to evaluate the significance in proliferation rate between vehicle and siEGFR or drug-treated cells. Student t tests were also used to evaluate significance in nEGFR expression levels by Nuance imaging analysis between vehicle-and dasatinib-treated cells. Differences were considered statistically significant if Ã , P < 0.05. Pearson correlation coefficient and Manders' overlap coefficient for colocalization were calculated using Nikon NIS-Elements software. Significance of strong interaction is considered for values !0.5 (36).
Results
TNBC cell lines and human tumors express nuclear localized EGFR
Six established TNBC cell lines were evaluated for EGFR expression (Fig. 1A) . All cell lines expressed total and activated forms of EGFR, in which the autophosphorylation status of EGFR at tyrosine 1068, 1173, and 1045, as well as the SFK-specific phosphorylation site, tyrosine 1101, were evaluated. All TNBC cell lines expressed activated SFKs, as observed in previous studies (refs. 37, 38; Fig. 1A ). Total and activated HER2 expression levels were low in all TNBC cell lines compared with HER2-positive cell lines SKBr3 and BT474.
Because TNBC cell lines expressed EGFR, we hypothesized that some cell lines may also express nEGFR. Variant levels of nEGFR expression were observed in TNBC cell lines by nuclear fractionation analysis (Fig. 1B) . The harvested nuclear lysate was free from contaminating cytoplasmic and ER-associated proteins, as indicated by lack of a-tubulin and calnexin. The nuclear protein Histone H3 was used as a loading and nuclear protein purity control. In addition, confocal immunofluorescent microscopy indicated strong nEGFR immunofluorescent staining in MDAMB468, SUM229, and SUM149 cells (Fig. 1B) incubated with secondary antibody only (data not shown). We further validated nEGFR expression using transmission electron microscopy ( Fig. 1C ). EGFR labeled with immunogold conjugated secondary antibodies indicated that EGFR was indeed localized in the nucleus, with localization in the nucleolus and around the nuclear envelope.
Given that nEGFR was expressed in established TNBC cell lines, we probed a human TMA containing 74 TNBC patient tumors for EGFR expression and localization. Pathologist analysis of tumors stained for EGFR via IHC indicated that 19% of the tumors expressed nEGFR (Fig.  1D) . Interestingly, nEGFR was highly localized to the nucleolus in more than 5% of nEGFR-positive tumors. In addition, some tumor sections contained concentrated nEGFR, whereas other areas of the same tumor lacked nEGFR expression. There was no signal detected from cores stained with secondary antibody only (data not shown). Collectively, these data demonstrate that TNBC cell lines and human tumors express nEGFR.
TNBC cells are resistant to cetuximab therapy, but dependent on EGFR for proliferation
To determine the role of EGFR in TNBC proliferation, studies were performed to knock down EGFR expression in various TNBC cell lines using an EGFR-directed siRNA pool. Loss of EGFR expression led to a 23% to 50% reduction in cell proliferation as compared to cells treated with vehicle or NT siRNA (Fig. 2) . Each cell line challenged with increasing doses of cetuximab (from 0.01 nmol/L to 100 nmol/L) demonstrated only minor reductions in proliferation. The cell lines MDAMB231 (Fig. 2B ) and MDAMB468 (Fig. 2D ) demonstrated a 15% reduction in proliferation upon treatment with 100 nmol/L of cetuximab, whereas the SUM159 ( Fig. 2A), SUM229 (Fig. 2C) , and SUM149 (Fig. 2E ) were unaffected at this dose. In addition, TNBC cell lines treated with increasing doses of dasatinib (0.01-100 nmol/L) were relatively resistant to growth inhibition. These results indicate that TNBC cell lines depend on EGFR for proliferation but are relatively resistant to cetuximab.
SFKs mediate the nuclear translocation of EGFR in TNBC
Previous studies from our laboratory indicate that SFKs influence nEGFR translocation in lung cancer (26, 30) . To investigate whether SFKs influence EGFR translocation from the plasma membrane to the nucleus in TNBC, constitutively active Src (caSrc) was overexpressed in SUM159, BT549, and MDAMB231 cells. The overexpression of caSrc, indicated by enhanced pSFK-Y419, led to increases in nEGFR expression (Fig. 3A) . Next, a negative regulator of Src, SLAP (39), was overexpressed in SUM149, SUM229, and MDAMB468 cells. The overexpression of SLAP, indicated by the expression of the Flag tag, led to decreases in nEGFR levels (Fig. 3B) . These studies indicate that modulation of SFK activity can influence nEGFR expression in TNBC cell lines.
Previous studies elucidating the functions of SLAP have identified that SLAP functions as an antagonist for Srcinduced mitogenesis partly through the binding of Src substrates and effector molecules (39) . Overexpression of SLAP resulted in its association with EGFR in three TNBC cell lines by coimmunoprecipitation analysis (Fig.  3C) . Immunoprecipitation with an IgG control yielded no signal (data not shown). Because EGFR deficient in tyrosine 1101 (Y1101) phosphorylation is hindered in nuclear translocation (Fig. 3C, Inset 1; ref. 30 ), we probed for phosphorylated EGFR at Y1101 post SLAP transfection. Indeed, TNBC cell lines overexpressing SLAP had decreased phosphorylation of EGFR at Y1101 (Fig. 3C ), which correlated with decreased nEGFR (Fig. 3B ). These data demonstrate that SFK phosphorylation of EGFR at Y1101 can influence nEGFR translocation in TNBC.
SFKs exhibit functional redundancy in their ability to influence nEGFR translocation
Previous reports suggest that the SFKs Yes and Lyn play a role in the nuclear translocation of EGFR (30) . However, experiments in Fig. 3 indicated that caSrc and SLAP could influence nEGFR translocation in TNBC cells, suggesting that global increased activity of SFKs may influence nEGFR expression. To test this hypothesis, stable clones of individual SFKs (Src, Yes, Lyn, Lck, Hck, Fyn, Blk, and Fgr) were engineered in the breast cancer cell line MCF-7. One or two stable clones were chosen for each SFK for comparison with an empty vector stable cell line (Fig. 4A) . The overexpression of each SFK led to the enhanced expression and nuclear translocation of EGFR. All cell lines were stimulated with 5 nmol/L EGF to promote the nuclear translocation of EGFR; however, a basal level of nEGFR was detected in nonstimulated SFK stable cells (data not shown). In addition, the stable overexpression of each SFK led to their increased activation, corresponding to a downregulation of the E3 ubiquitin ligase, c-Cbl (Fig. 4B) . This result may explain why an increase in total EGFR was observed in Fig.  4A . Collectively, these data suggest that SFKs play functional redundant roles in promoting nEGFR translocation.
Therapeutic inhibition of SFKs can block nEGFR translocation in in vitro and in vivo TNBC tumor models
Because the modulation of SFK activity influenced nEGFR, the SFK inhibitor dasatinib was utilized to determine whether it could abrogate EGFR translocation from the membrane to nucleus. Treatment of TNBC cells with dasatinib led to potent decreases in nEGFR levels (at 24 and 72 hours in SUM149 and SUM229, and at 72 hours in MDAMB468 cells; Fig. 5A ). Analysis of whole-cell lysate indicated that EGFR activity on Y1101 was inhibited by dasatinib at both time points. In addition, dasatinib treatment led to subsequent increases in non-nEGFR levels (Fig.  5A) . Nuance imaging and Inform software was further used to analyze nEGFR levels post-dasatinib treatment (Fig. 5B ). Cells were stained for EGFR, E-Cadherin, and DAPI; E-Cadherin and DAPI were used to create a spectral library that segmented each cell into cytoplasm and nucleus as previously described (34) . InForm software analysis of each cell line (n ¼ 2) demonstrated that dasatinib-treated cells trended toward less nEGFR staining as compared with vehicle-treated cells (P ¼ 0.08 at 48 hours).
To further characterize the effect of dasatinib on nonnEGFR expression, surface level EGFR was analyzed by flow cytometry. TNBC cells treated with dasatinib for 24 hours contained 30% to 42% more plasma membrane-bound EGFR as compared with vehicle-treated cells (Fig. 5C ). There was no additional increase in EGFR surface expression 72 hours posttreatment (data not shown). Together, these data suggest that EGFR accumulates on the plasma membrane when nEGFR translocation is blocked by dasatinib. Nonnuclear and nuclear proteins were harvested. nEGFR expression was quantitated using ImageJ software. B, a negative regulator of Src, SLAP, blocks nEGFR translocation in TNBC cell lines. Cells were transfected with SLAP-FLAG or an empty vector control for 48 hours before harvesting nonnuclear and nuclear proteins. nEGFR expression was analyzed. C, SLAP can interact with EGFR and decrease EGFR activation at tyrosine 1101. Cells were transfected with SLAP-FLAG or an empty vector control for 48 hours before harvesting whole-cell lysate. 250 mg of cell lysate was immunoprecipitated with an anti-SLAP antibody. The same lysate was subjected to immunoblot analysis for activation of EGFR at tyrosine 1101. pEGFR-Y1101 activity was quantitated using ImageJ software. Inset 1, EGFR mutated at tyrosine 1101 is deficient in nuclear localization. Vector, EGFR-WT, and EGFR-Y1101F were transfected into CHOK1 cells for 48 hours before stimulation with EGF (5 nmol/L, 45 minutes). Nonnuclear and nuclear proteins were harvested, and nEGFR expression was analyzed. To investigate whether therapeutic inhibition of SFKs can abrogate nEGFR translocation in vivo, MDAMB468 cells were established as xenograft tumors in female athymic nude mice. Mice were randomized into two groups receiving 50 mg/kg of dasatinib or vehicle once daily for 4 days. Figure 5D represents confocal immunofluorescence analyses of representative tumor sections harvested from either vehicle-or dasatinib-treated mice stained for EGFR. EGFR was highly nuclear localized in tumors from vehicle-treated mice. However, tumors harvested from dasatinib-treated mice harbored much less nEGFR, with a noticeable increase in plasma membrane localized EGFR expression. Immunoblot analysis of harvested tumors validated that dasatinib inhibited SFK activity; one dasatinib-treated tumor (#5) contained less total EGFR expression. The inhibition of nEGFR translocation was also visualized by immunohistochemical staining of tumors harvested from dasatinib-treated mice (Fig.  5E ). Interestingly, we found that dasatinib treatment of mice harboring colorectal tumors also contained less nEGFR expression within the tumor (Supplementary Fig.  S1 ), suggesting that SFKs may influence nEGFR translocation in different tumor types. Collectively, these data indicate that SFK inhibition prevents nEGFR translocation and enhances membrane accumulation of EGFR in vivo.
SFK inhibition can sensitize TNBC cells to cetuximab growth inhibition
Because SFK inhibition enhanced plasma membranebound EGFR expression, we hypothesized that TNBC cells may become more sensitive to cetuximab upon pretreatment with dasatinib. To investigate this, we performed proliferation assays after pretreating TNBC cells with dasatinib or vehicle for 24 hours, the time point at which an increase in surface level EGFR was detected, and subsequently treating cells with increasing doses of cetuximab for an additional 72 hours (Fig. 6 ). All cell lines pretreated with vehicle and subsequently treated with increasing doses of cetuximab demonstrated minor reductions in proliferation, consistent with data in Fig. 2 . In addition, cells treated with 25 nmol/L dasatinib monotherapy did not exhibit significant inhibition of proliferation. However, TNBC cell lines that received dasatinib for 24 hours before cetuximab treatment demonstrated significant reductions in proliferation over a wide range of cetuximab doses (1-100 nmol/L). SUM149 and SUM229 cells demonstrated significant reductions in proliferation at low doses of cetuximab (1 nmol/L), whereas MDAMB468 and MDAMB231 cells exhibited proliferation inhibition at higher doses of cetuximab (10 and 100 nmol/L). Collectively, these data suggest that the blockade of nEGFR translocation via SFK inhibition can increase TNBC cell sensitivity to cetuximab.
Discussion
TNBC is a subset of breast cancers that commonly overexpress the EGFR (3-6). Unfortunately, clinical trials targeting EGFR with cetuximab have yielded minimal benefit in TNBC (7, 8) , even with the addition of platinum-based chemotherapies (1, 5, 36) . Thus, understanding why TNBCs are intrinsically resistant to cetuximab has become an important clinical question. Over the last decade, numerous studies have identified a role for nEGFR in resistance to anti-EGFR agents (25, 26) . Previous studies from our laboratory demonstrated that NSCLC cell lines that had acquired resistance to cetuximab relied on nEGFR signaling to maintain their resistant phenotype (26) . On the basis of these studies, we hypothesized that nEGFR may be a critical molecular determinant for cetuximab resistance in TNBC.
In the current study, nEGFR was detected in a panel of established TNBC cell lines and human tumors (Fig. 1) . In prior studies, 38% of a 130 breast cancer patient cohort (15) and 40% of a 113 breast cancer patient cohort (19) stained positive for nEGFR, which was further correlated with worse overall survival. The heterogeneity observed in nEGFR expression in the current study of TNBC tumors highlights the importance of simultaneously targeting both nEGFR and non-nEGFR cell populations. Another interesting observation lies in the localization of EGFR in the nucleolus, functions that have yet to be investigated and may be playing important roles in TNBC pathogenesis. Collectively, the preclinical data presented in the current study suggest that nEGFR may be indicative of cetuximabresistant tumors warranting further investigation for its role as a predictive marker for cetuximab response in TNBC.
Recent work from our laboratory has found that SFKdependent phosphorylation of EGFR on Y1101 is a necessary and early event for EGFR translocation from the plasma membrane to the nucleus (30) . The current study aimed to identify whether this mechanism of nuclear translocation was present in TNBC. We found that three TNBC cell lines (MDAMB468, SUM149, and SUM229) with the highest levels of phosphorylated Y1101 also expressed the highest levels of nEGFR (Fig. 1A and B) . In addition, inhibition of SFK activity led to decreased phosphorylation of EGFR on Y1101 and reduced nEGFR levels (Figs. 3C and 5A and B). Interestingly, Fig. 5C indicates that surface level EGFR was enhanced within 24 hours of dasatinib treatment, even though a decrease in nEGFR expression was more prominent at later time points posttreatment (Fig. 5A and B) ; this suggests that the rate of nEGFR export, via its nuclear export sequence (28) , varies between cell lines. Collectively, these data suggest that SFK phosphorylation of EGFR on Y1101 may be a critical step for EGFR nuclear translocation in TNBC.
SFKs consist of 11 intracellular tyrosine kinases that are differentially expressed in a variety of cancers (40) . In the current study, eight individual SFKs were stably overexpressed, and found to function similarly in their ability to influence (i) the steady state expression of total EGFR, (ii) nEGFR translocation, and (iii) degradation of c-Cbl (Fig. 4) . These data suggest that SFKs exhibit functional redundancy in their ability to influence nEGFR translocation, and thus the use of broad-spectrum SFK inhibitors, such as dasatinib, may be highly beneficial in nEGFRpositive cancers.
In the current study, SFK inhibition of nEGFR translocation led to an accumulation of plasma membranebound EGFR and sensitization to cetuximab therapy (Figs. 5 and 6). Recent studies support our findings, where antitumorigenic effects of both cetuximab and dasatinib dual treatment with chemotherapy (41) and the use of noncompetitive monoclonal antibodies degrading the EGFR (42) have been documented in TNBC. In addition, a recent report demonstrated that targeting PCNA, a nEGFR substrate, could delay TNBC tumor growth (43) . In the current study, sensitization to cetuximab was observed after pretreatment of TNBC cells with dasatinib for 24 hours, the time point at which EGFR accumulation was detected on the plasma membrane due to the inhibition of nEGFR translocation. We speculate that the inhibition of nEGFR translocation drives TNBC cells to rely solely on classical membrane-bound EGFR signaling for sustained proliferation and survival signals; thus, TNBC cells become sensitized to cetuximab because cetuximab can abrogate classical EGFR signaling pathways. Previous studies in EGFR expressing NSCLC and HNSCC cell lines support this, where cell lines that lacked nEGFR expression were found to be more sensitive to cetuximab monotherapy (26, 30) . Currently, the growth inhibitory effect of cetuximab and dasatinib therapy is being accessed in vivo TNBC models in our laboratory, a critical step for the movement of this proposed drug combination into clinical trials. Collectively, the data presented herein indicate that the dual targeting of both nEGFR and plasma membrane-bound EGFR is necessary for the complete inhibition of EGFR's oncogenic functions, a therapeutic strategy that can be readily translated for the treatment of nEGFR expressing TNBC patients.
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Introduction
The TAM family of receptor tyrosine kinases (RTK) is composed of three family members: Tyro-3 (Sky), AXL (Ark or Ufo), and MerTK. Cognate ligand binding to TAM receptors on the cell surface leads to receptor dimerization, kinase domain activation, and auto/trans-phosphorylation of tyrosine residues located on each receptor's cytoplasmic tail (1) . The activation of TAM receptors stimulate PI3K/AKT and Ras/Raf/Mek/Erk (MAPK) signaling cascades, leading to increased cell survival, proliferation, migration, invasion, and angiogenesis (1) (2) (3) (4) .
TAM family overexpression and activation have been observed in many human cancers (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Recently, the AXL receptor has been implicated in cancer cell resistance to anti-EGFR tyrosine kinase inhibitors (TKI; refs. 12-17) and other chemotherapeutics (10, 15, 18) . Collectively, these data indicate that AXL functions as a potent oncogene that can modulate resistance to conventional and targeted cancer therapies.
Cetuximab is an anti-EGFR monoclonal antibody that has shown efficacy in treating head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (mCRC), and non-small cell lung cancer (NSCLC; refs. [19] [20] [21] [22] [23] [24] [25] [26] . Unfortunately, clinical studies indicate that most patients who initially respond to cetuximab eventually acquire resistance (27) (28) (29) . To understand the mechanisms of acquired resistance, we previously created a model in which the cetuximab-sensitive (Ctx S ) NSCLC cell line NCI-H226 was treated with increasing doses of cetuximab for a period of six months until resistant single cell clones emerged (30) . Analysis of cetuximab-resistant (Ctx R ) clones demonstrated that the expression of EGFR and its activation was dramatically increased because of dysregulated EGFR internalization and degradation without mutation of the receptor (30) . Overall, Ctx R cells remained highly addicted to the EGFR signaling network (30) (31) (32) .
On the basis of these previous findings, we investigated whether the AXL receptor played a role in cetuximab resistance. Examination of in vitro NSCLC and HNSCC models of acquired resistance indicated that AXL was highly overexpressed and activated in Ctx R cells. Further analysis indicated that Ctx R cells had increased dependency on AXL for cellular proliferation, EGFR activation, and MAPK signaling. AXL activity was also examined in tumors harvested from de novo-acquired Ctx R NCI-H226 xenografts, where AXL was highly activated and associated with the EGFR. Finally, AXL was overexpressed and hyperactivated in HNSCC patient-derived xenografts (PDX) that were intrinsically resistant to cetuximab therapy. Collectively, this work indicates that AXL plays a role in cetuximab resistance and provides rationale for the clinical evaluation of anti-AXL therapeutics for the treatment of cetuximab resistant cancers.
Materials and Methods
Cell lines and development of acquired resistance
The human NSCLC cell line NCI-H226 was purchased from ATCC and maintained in 10% FBS in RPMI-1640 (Mediatech Inc.) with 1% penicillin and streptomycin. The HNSCC cell line UM-SCC1 was provided by Dr. Thomas E. Carey (University of Michigan, Ann Harbor, MI) and maintained in 10% FBS in Dulbecco's Modified Eagle Medium (DMEM) with 1% penicillin and streptomycin. The development of Ctx R cells has been previously described (30) (31) (32) . All Ctx R cell lines were validated to express wild-type (WT) EGFR by sequencing.
Materials
R428 was purchased from Selleckchem and MAb173 was produced in the laboratory of Dr. Parkash Gill (Department of Medicine and Pathology, University of Southern California, Los Angeles, CA). Cetuximab (ICM-225; Erbitux) was purchased from University of Wisconsin Pharmacy. EGF was purchased from Millipore and TGFa was purchased from Sigma-Aldrich.
Antibodies
All antibodies were purchased from commercial sources as indicated below:
R&D Systems: AXL (for immunoblotting) and pAXL-Y779. Cell Signaling Technology: pAXL-Y702, pEGFR-Y1068, pMAPK (T202/Y204), MAPK, p-cRAF (S289/296/301), cRAF, p-AKT (S473), AKT, p-rpS6 (S240/244), rpS6, p-c-Jun (S73), c-Jun, and GAPDH. Santa Cruz Biotechnology Inc.: pEGFR-Y1173, AXL (for immunoprecipitation), and horseradish peroxidase (HRP)-conjugated goat-anti-rabbit IgG, goat-anti-mouse IgG, and donkey-anti-goat IgG. Life Technologies: AXL (for immunofluorescence). Abcam: EGFR. Calbiochem: a-tubulin.
siRNA and transfection
Ctx R cells were transiently transfected with AXL siRNA (siAXL; ON-TARGETplus, SMARTpool #L-003104; Dharmacon), siEGFR (ON-TARGETplus, SMARTpool #L-003114; Dharmacon), siHER2 (ON-TARGETplus, SMARTpool #L-003126; Dharmacon), siHER3 (ON-TARGETplus, SMARTpool #L-003127; Dharmacon), p44/42 MAPK (ERK1/2) siRNA (Cell Signaling Technology; #6560), AKT1 siRNA (ON-TARGETplus, SMARTpool #L-003000; Dharmacon), c-Jun siRNA (ON-TARGETplus, SMARTpool #L-003268; Dharmacon), or nontargeting siRNA (siNT; ON-TARGETplus Non-targeting Pool, #D-001810; Dharmacon) using Lipofectamine RNAiMAX according to the manufacturer's instructions (Life Technologies).
Immunoblot analysis
Whole-cell lysis was performed as previously described (31, 33) . Enhanced chemiluminescence (ECL) detection system was used to visualize proteins. For detection of phosphorylated AXL, cells were treated with pervanadate (0.12 mmol/L Na 3 VO 4 in 0.002% H 2 O 2 ) for 2 minutes before cell lysis, a method previously described (10) . EGF and TGFa ligands were added to growth media 45 minutes before lysis.
Immunoprecipitation
Cells were processed for immunoprecipitation as previously described (34) . Five-hundred micrograms of protein, 2 mg of anti-AXL (Santa Cruz Biotechnology), cetuximab, or IgG antibody (Santa Cruz Biotechnology) were used.
Cell proliferation assay
Crystal violet assay and Cell Counting Kit-8 (Dojindo Molecular Technologies) were performed as previously described (31, 35) . Cellular proliferation was measured 72 hours after siRNA or drug treatment.
Flow cytometric analysis
Cells were processed as previously described (36) and analyzed using a FACSCalibur flow cytometer (BD Biosciences). Propidium iodide was added to each sample at a final concentration of 5 mg/mL. Histogram analysis was performed using FlowJo software (TreeStar Inc.).
Plasmids, transfection, and stable cell line construction pDONR223-AXL (Plasmid 23945) was purchased from Addgene and subcloned into the BamH1/EcoR1 restriction sites of the pcDNA6.0 expression vector (Life Technologies). Stable transfection was performed using Lipofectamine LTX and Opti-MEM I (Life Technology) commencing 48 hours after transfection via 6 mg/mL blasticidin to the growth media. Single-cell clones were chosen for expansion and validation for AXL expression.
cDNA synthesis and qPCR
Total RNA and cDNA synthesis were prepared as previously described (34) . All reactions were performed in triplicate. To determine the normalized value, 2
DDCt values were compared between AXL and 18S, where the change in crossing thres-
Cetuximab-resistant cell line xenografts and PDXs Ctx R cell line xenografts were established as previously described (31) , and HNSCC PDXs were established and evaluated for cetuximab response as described in Supplementary Materials and Methods.
Statistical analysis
Student t tests were used to evaluate differences in proliferation, AXL mRNA expression, and pAXL-Y779 expression levels by IHC. Differences were considered statistically significant if Ã , P < 0.05. 
Results
AXL is overexpressed and activated in a model of acquired resistance to cetuximab
The NSCLC Ctx R clones HC1, HC4, and HC8 have been previously shown to be resistant to increasing doses of cetuximab as compared to the Ctx S NCI-H226 parental cell line HP (30, 31) . Analysis of Ctx R clones HC1, HC4, and HC8 demonstrated that all clones expressed increased AXL mRNA and protein as compared to HP cells (Fig. 1A) . Furthermore, AXL exhibited increased phosphorylation on tyrosine 702 and 779 in all Ctx R clones. In addition, MAPK and AKT pathways were hyperactivated and there was increased expression and phosphorylation of the transcription factor c-Jun in Ctx R clones. Moreover, plasma membrane levels of AXL were detected via flow cytometry, where Ctx R cells had approximately 50% to 80% more surface AXL expression as compared to HP cells (Fig. 1B) . Collectively, these data demonstrate that AXL is overexpressed and activated in established clones with acquired resistance to cetuximab.
AXL and EGFR cooperate in Ctx
R clones to sustain proliferation via MAPK and c-Jun Ctx R clones are known to be highly dependent on EGFR for proliferation (30) (31) (32) . To determine whether AXL also plays a role in Ctx R cell proliferation, proliferation assays were performed 72 hours after transfection with a pooled siAXL or siNT ( Fig. 2A) . Loss of AXL expression resulted in statistically significant inhibition of proliferation (25%-35%) in all three Ctx R clones. As compared with parental HP cells, the Ctx R clones demonstrated significantly greater decreases in proliferation after AXL knockdown (P < 0.01). Analysis of Ctx R clones after AXL knockdown demonstrated that EGFR activation was severely diminished at both tyrosine 1068 and 1173, autophosphorylation sites responsible for recruiting Grb2 and Shc ( Fig.  2B; ref. 37 ). In addition, the activation of c-Raf, p44/42 MAPK, AKT, and ribosomal protein S6 (rpS6) were diminished in all Ctx R clones upon AXL knockdown, whereas the activation of these molecules were relatively unchanged or slightly increased in HP cells (Fig. 2B) . Interestingly, ablation of HER2 or HER3 receptors, previously shown to be hyperactivated in Ctx R cells (30), did not affect the phosphorylation of EGFR at either tyrosine site (Fig. 2B, inset) . Collectively, these data demonstrate that Ctx R clones are dependent on AXL for cellular proliferation via EGFR activation and downstream signaling.
To determine whether AXL and EGFR were physically associated in Ctx R clones, coimmunoprecipitation experiments were performed and indicated that AXL was associated with EGFR in all Ctx R clones but not parental cells (Fig. 2C ). EGFR and AXL cooperation was further analyzed by reciprocally knocking down EGFR expression with siRNA (Fig. 2D) . EGFR knockdown A B Figure 1 . The RTK AXL and its downstream effector molecules are overexpressed in cetuximab resistant cells. A, whole-cell lysate was harvested from the Ctx S parental cell line (HP) and three Ctx R cell clones (HC1, HC4, and HC8) followed by immunoblotting for the indicated proteins. GAPDH was used as a loading control. Total AXL protein expression was quantitated using ImageJ software. AXL mRNA expression was detected by qPCR and normalized to AXL expression in HP cells (n ¼ 3 in three independent experiments). 18S was used as an endogenous control. B, surface level AXL expression was detected by flow cytometry and normalized to HP. IgG-stained cells were used as a background control (n ¼ 3 in two independent experiments). Data, mean AE SEM. ÃÃ , P < 0.01. (Fig. 2E ). This experiment indicated that knockdown of p44/42 MAPK led to a loss of AXL mRNA and protein expression, whereas AKT1 did not regulate AXL expression. These results suggest that EGFR regulates AXL expression specifically through MAPK signaling.
Previous studies indicated that the AXL promoter contains binding motifs for AP-1 family transcription factors, in which phorbol myristate acetate (PMA) stimulation of leukemia cells led to increased AXL expression through MAPK signaling to (38) . Because Ctx R clones were found to overexpress c-Jun (Fig. 1A) , we hypothesized that c-Jun may function downstream of MAPK to regulate AXL mRNA expression. To investigate this, c-Jun was knocked down with siRNA (Fig. 2F) , leading to an approximate 35% to 55% decrease in AXL mRNA levels. Moreover, there was a loss of AXL protein expression, which appeared similar to the levels detected after EGFR or MAPK knockdown ( Fig. 2D and E) . Importantly, this led to a loss of EGFR activation in Ctx R clones, but not in parental HP cells, indicating that AXL is required for EGFR activation and subsequent signaling in the resistant setting. Collectively, these data indicate that AXL expression and subsequent EGFR activation are regulated through the MAPK/c-Jun signaling pathway in Ctx R clones.
Ctx R cells are sensitive to anti-AXL monoclonal antibody and TKI therapies
Because Ctx R clones were sensitive to AXL knockdown by siRNA, we hypothesized that these cells would also be sensitive to anti-AXL therapeutics. First, we tested the ability for the anti-AXL monoclonal antibody MAb173 to inhibit Ctx R cell proliferation (Fig. 3A) . Ctx R clones were significantly growth inhibited upon treatment with increasing doses of MAb173, whereas Ctx S HP cells were less sensitive. In addition, the growth-inhibitory effects of Ctx R clones were statistically decreased from the effect on HP cells when treated with 50 and 100 mg/mL of MAb173 (P < 0.01). Consistent with previous studies (9), MAb173 induced AXL degradation (Fig.  3B) . Interestingly, total EGFR protein levels were reduced upon MAb173 treatment of Ctx R clones, in addition to loss of MAPK signaling. MAb173 did not affect the activation of EGFR or MAPK signaling in HP cells.
Next, the small-molecule TKI R428, which has greater than 100-fold selectivity for AXL as compared with EGFR or Tyro and 50-fold greater affinity than Mer (39), was tested for therapeutic benefit in Ctx R clones (Fig. 4A) . All Ctx R clones demonstrated robust antiproliferative effects upon treatment with 0.8 and 1 mmol/L of R428, whereas HP cells were less sensitive at these concentrations. In addition, the growthinhibitory effects of Ctx R clones were statistically decreased from the effect on HP cells when treated with 0.8 and 1 mmol/L of R428 (P < 0.01). Analysis of Ctx R clones after treatment, via pan-tyrosine, demonstrated that AXL phosphorylation was inhibited with 1.0 mmol/L of R428, the same dose that elicited antiproliferative responses (Fig. 4B) . In addition, R428 treatment led to a loss of EGFR phosphorylation on tyrosine 1068 and MAPK signaling, whereas these targets were relatively unaffected in HP cells (Fig. 4C) . Interestingly, both MAb173 and R428 did not influence the apoptosis pathway in Ctx R clones (data not shown), indicating that AXL more predominantly activates growth-promoting pathways in resistant cells.
AXL activation and overexpression confers cetuximab resistance in vitro and in vivo mouse xenograft models
To confirm the role of AXL in cetuximab resistance, AXL was stably overexpressed in the Ctx S parental cell line HP (Fig. 5A ). Immunoprecipitation analysis of HP-AXL stable cells indicated that AXL was phosphorylated on tyrosine 779, resulting in Research.
on August 20, 2014. © 2014 American Association for Cancer cancerres.aacrjournals.org Downloaded from increased phosphorylation of EGFR and downstream MAPK signaling. Cetuximab dose-response proliferation assays demonstrated that HP-AXL cells were statistically more resistant to cetuximab as compared with HP-Vector cells (P < 0.01; Fig. 5B ). HC4 cells served as a cetuximab-resistant control in these experiments. These data demonstrate that the stable overexpression of AXL can confer resistance to cetuximab in a Ctx S cell line, supporting a putative role for AXL in the development of cetuximab resistance.
We previously reported that Ctx R clones overexpressed EGFR ligands (36) ; however, whether EGFR ligands influenced cetuximab resistance through regulating AXL activity and/or association with the EGFR was not investigated. Therefore, HP cells were stimulated with two EGFR ligands, EGF or TGFa, and subsequently measured for AXL activation, association with the EGFR, and cetuximab response (Fig. 5C) . Analysis of HP cells after ligand stimulation indicated that both ligands led to increased AXL activation and association with the EGFR (detected by immunoprecipitation analysis). In addition, incubation with either ligand resulted in increased resistance to cetuximab. Interestingly, the ligand for AXL, Gas6, was not overexpressed in Ctx R clones and did not drive resistance in HP cells (data not shown). Collectively, these data suggest that EGFR ligands may influence cetuximab resistance through stimulating AXL activation and association with the EGFR.
To further analyze the role of AXL in cetuximab resistance, we developed de novo tumors with acquired resistance to cetuximab in vivo (31, 32) . To develop de novo-acquired resistance, the Ctx S cell line NCI-H226 was inoculated unilaterally into the dorsal flank of 11 athymic nude mice (Fig. 5D ). Once tumors reached approximately 100 mm 3 , 4 mice were treated with IgG control antibody (1 mg/mouse) and 7 mice were treated with cetuximab (1 mg/mouse) by intraperitoneal injection twice weekly. Tumors treated with IgG grew rapidly (tumors denoted as IgG-1 to IgG-4 in Fig. 5D ), whereas all cetuximab-treated tumors displayed initial growth control. Acquired resistance was observed after approximately 30 days of cetuximab exposure in 6 of the cetuximab-treated mice (tumors denoted as Ctx R -1 to Ctx R -5, and Ctx R -7), at which point there was marked tumor growth in the presence of continued cetuximab therapy (Fig. 5D) . One mouse was continued on cetuximab for 90 days until a significant increase in tumor growth was observed (Ctx R -6). Once tumors reached 2,000 mm 3 , they were harvested and processed for immunoblot analysis (Fig. 5D) and IHC (Fig. 5E) . To detect the levels of total and activated AXL (Y779), immunoprecipitation analysis was performed from tumor lysates. Strikingly, a double banding pattern for total AXL was observed in all Ctx R tumors, whereas a single AXL band was observed in the IgG-treated tumors. The upper band corresponds to a shift in AXL molecular weight due to the presence of phosphorylated AXL, which was detected by the phospho AXL-Y779 antibody (Fig. 5D, arrows) . In addition, AXL was associated with EGFR only in the Ctx R tumors by immunoprecipitation (Fig. 5D) . Analysis of whole-cell lysate indicated that EGFR was also highly activated (indicated by tyrosine 1068 phosphorylation) in the Ctx R tumors that expressed the highest levels of pAXL-Y779. IHC analysis of IgG versus Ctx R tumors revealed that Ctx R tumors had statistically significant increases in pAXL-Y779 staining (Fig. 5E) . Collectively, these data demonstrate that AXL overexpression and/or activation plays a role in acquired resistance to cetuximab in vitro and in vivo.
To expand these findings to a more clinically relevant model system, we determined whether there was a correlation between cetuximab response and AXL expression in PDXs established directly from surgically resected HNSCCs. Six PDXs were established from patients who had not received prior cetuximab therapy (see Supplementary Table S1 for clinical characteristics of patients before surgery). For each PDX, dual flank tumors were established in 16 athymic nude mice. When tumors reached approximately 200 mm 3 , the mice were stratified into two treatment groups: control (vehicletreated) and cetuximab (n ¼ 8 mice/16 tumors per group). After completing the treatment regimen, tumor growth was monitored to evaluate response to therapy. Overall, there were three cetuximab-sensitive PDXs (UW-SCC36, UW-SCC22, and UW-SCC52) and three cetuximab-resistant PDXs (UW-SCC1, UW-SCC17, and UW-SCC25; Fig. 6 ).
PDXs harvested from early-passaged tumors before treatment were evaluated for AXL expression and activation by IHC analysis (Fig. 6) . The cetuximab-sensitive PDXs had low levels of AXL and pAXL-Y779 staining, with UW-SCC36 having nearly absent expression of both markers. In comparison, the three cetuximab-resistant PDXs expressed 1.8-to 2.5-fold increases in pAXL-Y779 expression, and 2.5-to 4.3-fold increases in total AXL expression as compared with the staining intensity . Whole-cell lysate was harvested and subjected to immunoblot analysis. a-Tubulin was used as a loading control. 500 mg of protein was subjected to immunoprecipitation with an anti-AXL antibody for analysis of pAXL-Y779. IgG heavy chain staining from the IB:AXL blot was used as a loading control. B, HP-AXL, HP-Vector, or HC4 cells were treated with increasing doses of cetuximab (1-100 nmol/L) for 72 hours before performing proliferation assays. Proliferation is plotted as a percentage of growth relative to vehicle treated cells (n ¼ 6 for four independent experiments). Data, mean AE SEM. ÃÃ , P < 0.01. C, HP cells were stimulated with 50 ng/mL of EGF or TGFa for 45 minutes before harvesting whole-cell lysate. Of note, 500 mg of protein was subjected to immunoprecipitation with an anti-AXL antibody for analysis of EGFR association. Proliferation assays were performed 72 hours after treatment with increasing doses of cetuximab and either 50 ng/mL EGF or TGFa. Proliferation is plotted as a percentage of growth relative to vehicle-treated HP cells (n ¼ 8 for three independent experiments). Data, mean AE SEM. AXL plays a role in acquired resistance to cetuximab in HNSCC To further investigate whether AXL plays a more global role in acquired resistance to cetuximab, we developed a model of acquired resistance to cetuximab using the Ctx S parental cell line UM-SCC1 (30) . This resulted in a parental SCC1 cell line (SP) and three cetuximab-resistant clones (SP7, SP8, and SP11). SP cell growth was inhibited upon treatment with increasing doses of cetuximab, while the three HNSCC Ctx R clones remained resistant (Fig. 7A) . Analysis of HNSCC Ctx R clones indicated that all clones had increased steady-state expression of AXL as compared with SP (Fig. 7B) . In addition, each clone demonstrated increased activation of c-Raf, p44/42 MAPK, AKT, rpS6, and c-Jun (Fig. 7B) . To determine whether AXL influenced HNSCC Ctx R cell proliferation, cells were transfected with siAXL or NT siRNA and proliferation assays were performed. Loss of AXL expression resulted in a significant inhibition in cellular proliferation (20%-25%) in HNSCC Ctx R clones, while parental SP cells were nonresponsive (Fig. 7C) . The growth-inhibitory effects of siAXL in HNSCC Ctx R clones were statistically decreased compared with the effect on SP cells (P < 0.01). Furthermore, all HNSCC Ctx R clones expressed diminished activation of EGFR (by tyrosine 1068 phosphorylation) as well as MAPK and AKT signaling pathways upon AXL knockdown, whereas the activation of these molecules was relatively unchanged or slightly increased in SP cells. Collectively, these data suggest that AXL plays a role in acquired resistance to cetuximab in HNSCC.
Discussion
Cetuximab is a commonly used anti-EGFR monoclonal antibody that has demonstrated efficacy in treating in HNSCC, mCRC, and NSCLC (19) (20) (21) (22) (23) (24) (25) (26) . Although cetuximab treatment has yielded clinical benefit, both intrinsic and acquired resistance are common outcomes. Recently, a novel mutation was identified in the EGFR (S492R) that mediates resistance to cetuximab (40) ; however, resistance also occurs in the WT setting. Multiple mechanisms of cetuximab resistance exist, including upregulation of EGFR ligands (41), nuclear translocation of EGFR (36) , oncogenic shift to vascular endothelial growth factor receptor-1 (VEGFR-1; ref. 42) , and constitutive activation of downstream signaling molecules such as KRAS (43) and c-Src (44) . This study is the first to describe a role for AXL in mediating cetuximab resistance in the setting of wild type (WT) EGFR, and thus provides rationale for the development and use of anti-AXL therapeutics for treatment of Ctx R tumors. Cetuximab resistance is challenging to study due to the lack of access to patient tissue upon relapse. To model Ctx clones. The regulation of AXL mRNA was contingent on MAPK and c-Jun because knockdown of either decreased AXL expression ( Fig. 2E and F) .
These data support a positive-feedback loop that occurs in EGFR-dependent Ctx R cells (Fig. 8 ). In this model, resistance is characterized by increased EGFR ligand production, dimerization, and transactivation of AXL and EGFR. This interaction results in hyperactivated MAPK/c-Jun signaling, upregulation of AXL mRNA expression, and maintenance of constitutive EGFR activation and cetuximab resistance. The de novo Ctx R cell line xenografts support this model, as Ctx R tumors expressed increased total and activated AXL (especially as compared with IgG-1 and IgG-2). Although c-Jun was capable of regulating AXL mRNA expression in Ctx S parental cells, this regulation did not reduce EGFR activity (Fig. 2F) , suggesting that EGFR and AXL are not coupled in Ctx S cells. Because of limited availability of patient tissue after cetuximab failure, the expression status of AXL and pAXL-Y779 was evaluated in intrinsically resistant HNSCC PDXs. PDXs are clinically relevant cancer models because they accurately maintain many aspects of the parental tumor, including its histology, gene expression profile, copy number variance, and metastatic patterns (45, 46) . In this study, total and activated AXL were highly overexpressed in HNSCC PDXs that were resistant to cetuximab (Fig. 6) . The strong correlation between AXL and cetuximab resistance observed in the PDXs supports Relative to NT (%) Figure 7 . AXL mediates acquired resistance to cetuximab in HNSCC. A, Ctx R cell clones (SP7, SP8, and SP11) and the Ctx S parental cell line (SP) were treated with increasing doses of cetuximab (1, 10, and 100 nmol/L) for 72 hours before performing proliferation assays. Proliferation is plotted as a percentage of growth relative to vehicle-treated cells (n ¼ 5 for three independent experiments). B, whole-cell lysate was harvested from cells followed by immunoblotting for the indicated proteins. a-Tubulin was used as a loading control. Total AXL protein expression was quantitated using ImageJ software. C, cells were incubated with siAXL or nontargeting (NT) siRNA for 72 hours before performing proliferation assays or isolation of whole-cell lysate and immunoblotting for indicated proteins. a-Tubulin was used as a loading control. Proliferation is plotted as a percentage of growth relative to NT-transfected cells (n ¼ 3 for three independent experiments). Data, mean AE SEM. ÃÃ , P < 0.01. the mechanistic work performed in this study and suggests that AXL may mediate both intrinsic and acquired resistance to cetuximab.
To date, AXL has been identified to play a role in resistance to EGFR TKIs in NSCLC (16), HNSCC (13) , and TNBC (14) . In NSCLC, AXL was overexpressed and activated in EGFR-mutant erlotinib-resistant cells, where AXL inhibition resensitized tumor cells to erlotinib (13, 16) . In this study, AXL inhibition was sufficient to inhibit the growth of Ctx R clones, but did not resensitize Ctx R clones to cetuximab (data not shown). This likely occurred because AXL inhibition robustly decreased EGFR activation; thus, adding cetuximab provided no further benefit. Although AXL inhibition led to robust antiproliferative effects in Ctx R clones, cell growth was not completely arrested, suggesting that other RTKs may influence resistance. Previous work from our laboratory and others suggests that signaling emanating from HER2:HER3 heterodimers play a role in resistance to anti-EGFR agents (30, 47) . Thus, targeting AXL and either HER2 or HER3 may result in even more robust antiproliferative responses because EGFR signaling could be abrogated through AXL inhibition and HER2:HER3 signaling could be blocked with anti-HER2 or HER3 agents. Ultimately, this approach may lead to a complete loss of HER family signaling capabilities and serve as a powerful strategy for the treatment of Ctx R cancers. With increasing evidence supporting the role of AXL in resistance to anti-EGFR agents, the development of anti-AXL therapeutics is essential. In this study, two novel anti-AXL therapeutics were tested: MAb173, an anti-AXL-neutralizing monoclonal antibody, and R428, a selective small-molecule AXL TKI. In previous studies, researchers demonstrated that AXL was hyperactivated in Kaposi sarcoma and that MAb173 induced AXL endocytosis and degradation (9) . In addition to AXL, total EGFR expression was decreased upon MAb173 treatment of Ctx R cells (Fig. 3B) , supporting the existence of AXL and EGFR heterodimers and the utility of this antibody in the setting of cetuximab resistance. Furthermore, EGFR was not degraded in MAb173-treated HP cells, which lack AXL and EGFR association (Fig. 2C) . The anti-AXL TKI R428 has also shown antitumorigenic effects in multiple cancer models, including breast cancer (14, 39) and HNSCC (13) . The differences in growth inhibition observed between MAb173 and R428 may result from off-target effects of R428, leading to more robust antiproliferative responses. R428 has now entered phase I clinical trials, whereas MAb173 is still undergoing preclinical testing.
Overall, AXL plays a key role in tumor growth, metastasis, angiogenesis, and resistance to anti-EGFR agents (12) (13) (14) (15) (16) (17) . In addition, AXL inhibition has been shown to enhance the efficacy of standard chemotherapy regimens (10, 15, 18) . With AXL at the forefront, Tyro and Mer receptors also influence parameters of tumor biology (1, 4) . In fact, both Tyro and Mer receptors were differentially overexpressed in the current Ctx R models (unpublished data), promoting further research on the global role of TAM receptors in cetuximab resistance. Collectively, the studies herein have strong potential for translation into future clinical trials and therapies for patients with cetuximab-resistant tumors. 
